NCT06873542View on ClinicalTrials.gov

A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

December 7, 2022

Study Completion Date

January 2, 2024

Conditions
Solid Tumors
Interventions
DRUG

DC05F01

DC05F01 capsule

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

250117

Shandong Cancer Hospital, Jinan

Sponsors
All Listed Sponsors
lead

Heronova Pharmaceuticals

INDUSTRY

NCT06873542 - A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter